Select a medication above to begin.
Veozah
fezolinetant
Black Box Warnings .
Hepatotoxicity Risk
hepatotoxicity has occured; monitor LFTs before tx start, do not start if ALT or AST >2x ULN or if bilirubin >2x ULN; monitor LFTs monthly for 1st 3mo, then at 6mo and 9mo after tx start; D/C immediately if liver injury s/sx (new onset fatigue, appetite decr, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, abdominal pain), if ALT or AST >5x ULN, or if AST or ALT >3x ULN and bilirubin >3x ULN; if AST or ALT >3x ULN, monitor LFTs more frequently until resolution
Adult Dosing .
Dosage forms: TAB: 45 mg
vasomotor sx, mod-severe menopausal
- [45 mg PO qd]
- Info: do not cut/crush/chew tab
renal dosing
- [see below]
- eGFR <30: contraindicated
- HD/PD: not defined
hepatic dosing
- [see below]
- cirrhosis: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.